Male sex hormone loss aids brain tumour growth (original) (raw)

Depletion of sex hormones that enable male development induces neuroinflammation that disrupts hormonal signalling and immune responses against brain tumours.

By

  1. Frederick S. Varn
    1. Frederick S. Varn is at the Jackson Laboratory for Genomic Medicine, Farmington, Connecticut 06032, USA.

Men typically have a higher incidence of cancer and poorer outcomes compared with women1. Although the mechanisms underlying these sex differences remain under investigation, they are thought to be mediated by sex hormones called androgens, which are needed for the body to develop male characteristics. These hormones have been shown to weaken the immune system’s ability to respond to cancer, and blocking androgen signalling can enhance the success of immunotherapy for a number of tumour types2,3. However, writing in Nature, Lee et al.4 report that androgens have the opposite effect on the growth of brain tumours.

Access options

Access Nature and 54 other Nature Portfolio journals

Get Nature+, our best-value online-access subscription

$32.99 / 30 days

cancel any time

Subscribe to this journal

Receive 51 print issues and online access

$199.00 per year

only $3.90 per issue

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Additional access options:

doi: https://doi.org/10.1038/d41586-026-01159-7

References

  1. Cook, M. B., McGlynn, K. A., Devesa, S. S., Freedman, N. D. & Anderson, W. F. Cancer Epidemiol. Biomarkers Prev. 20, 1629–1637 (2011).
    Article PubMed Google Scholar
  2. Yang, C. et al. Immunity 55, 1268–1283 (2022).
    Article PubMed Google Scholar
  3. Xiao, T. et al. Nature Rev. Cancer 24, 338–355 (2024).
    Article PubMed Google Scholar
  4. Lee, J. et al. Nature https://doi.org/10.1038/s41586-026-10451-5 (2026).
    Article Google Scholar
  5. Ostrom, Q. T., Rubin, J. B., Lathia, J. D., Berens, M. E. & Barnholtz-Sloan, J. S. Neuro Oncol. 20, 576–577 (2018).
    Article PubMed Google Scholar
  6. Rodríguez-Lozano, D. C., Piña-Medina, A. G., Hansberg-Pastor, V., Bello-Alvarez, C. & Camacho-Arroyo, I. Front. Endocrinol. 10, 16 (2019).
    Article Google Scholar
  7. Werner, C. K. et al. Mol. Cancer Ther. 19, 2163–2174 (2020).
    Article PubMed Google Scholar
  8. Haddad, A. F. et al. Neurooncol. Adv. 3, vdab100 (2021).
    Article PubMed Google Scholar

Download references

Competing Interests

The author declares no competing interests.

Subjects

Latest on: